Arsenic trioxide, a treatment used for acute promyelocytic leukemia, may help extend lifespan in patients with glioblastoma brain cancer, a new study reports.
Researchers have identified a biomarker that can help predict a patient's prognosis and response to therapies for glioblastoma brain cancer subtypes.
UCLA researchers report erlotinib, an FDA approved drug, reduces glucose uptake in glioblastoma, effectively cutting off nutrients and energy supply to the tumor.
A new study reports researchers have identified a mechanism that aids the growth of glioblastoma brain cancer. By blocking the mechanism, researchers were able to halt the progression of the tumors.
A new Baylor study reveals the CD44s molecule gives glioblastoma brain cancer cells a survival advantage. Removing CD44s from cancer cells and treating with erlotinib helped to promote the death of cancer cells than by just treating the cancer with erlotinib alone, researchers said.
Researchers discover a mechanism that may underpin the progression of glioblastoma brain cancer development.
Researchers have developed a new drug that could help prolong the lives of people with glioblastoma brain cancer.
Researchers are developing nanocarriers that are twice as effective as liposomes at reaching glioblastoma brain tumors.
A lipid nanocarrier small enough to pass the blood-brain barrier could be an effective method for delivering chemotherapy medications to help fight glioblastoma brain tumors, a new study reports.